Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 10/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7563867 | 0.87 | NR3C2 (0.39) | NR3C2TP53KIF11POLBNR3C1 | |
| SCHEMBL6625675 | 0.81 | KMT2A (0.50) | NR3C2NR3C1RAF1BRAFMMP12 | |
| SCHEMBL9727556 | 0.78 | BCAT1 (0.45) | NR3C2TP53KIF11POLBNR3C1 | |
| SCHEMBL7556723 | 0.76 | MMP12 (0.46) | NR3C2TP53NR3C1PGRMAPT | |
| SCHEMBL10491107 | 0.75 | MAPT (0.46) | NR3C2TP53MAPTTHRBMMP12 | |
| SCHEMBL9427952 | 0.74 | CHRM1 (0.40) | TP53MAPT | |
| SCHEMBL9032890 | 0.74 | CHRM1 (0.32) | — | |
| SCHEMBL7964385 | 0.73 | NR3C2 (0.43) | NR3C2NR3C1 | |
| SCHEMBL9480245 | 0.73 | MMP12 (0.43) | NR3C2TP53PGRMAPTTHRB | |
| SCHEMBL7670892 | 0.72 | AR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186021-A1 | Substituted benzo-nitro-heterocycles | BAYER CROPSCIENCE AG (DE) | 2004-09-23 | — | — | US | disclosed |
| EP-1409484-A1 | SUBSTITUTED BENZO-NITRO-HETEROCYCLES | Bayer CropScience AG (DE) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003006461-A1 | SUBSTITUTED BENZO-NITRO-HETEROCYCLES | BAYER CROPSCIENCE AG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186021-A1 | Substituted benzo-nitro-heterocycles | NQO1, CBR1, MT-ND1 | NR3C2 1344/4885TP53 2553/4885KIF11 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.